NASDAQ:LYEL

Lyell Immunopharma Stock Predictions

etoro logo Buy LYEL
*Your capital is at risk
$12.57
-2.32 (-15.58%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

LYEL Prediction Chart

LYEL Predictions History

Latest community submissions for LYEL.
Predictor Target Session Target Price Result Direction Accuracy Score
Jan 20, 2026 $22.77 -4.17% $23.90 X 95.26% 0
Jan 20, 2026 $24.38 +2.61% $23.90 V 97.99% 1
Jan 20, 2026 Bullish $23.90 V 1
Jun 5, 2025 $13.03 -3.25% $11.46 V 86.28% 1
Jun 5, 2025 $13.20 -2.03% $11.46 V 84.85% 1
Jun 5, 2025 Bullish $11.46 V 0
Feb 18, 2025 $0.590 -95.16% $0.609 V 96.84% 1
Feb 18, 2025 $0.598 -95.10% $0.609 V 98.07% 1
Feb 18, 2025 Bullish $0.609 X 0
Mar 6, 2024 $2.57 -94.88% $2.64 X 97.31% 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for LYEL with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT LYELL IMMUNOPHARMA, INC.
Lyell Immunopharma
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE